Table 1.
Patients’ characteristics by to study periods (n = 40)
| 2000-2007 (n = 24) |
2008-2014 (n = 16) |
|
|---|---|---|
| Frequency (%) | 60 | 40 |
| Age at diagnosis, years (mean ± SD) | 10.9 ± 4.5 | 11.6 ± 4.9 |
| Infants (n (%)) | 3 (12.5) | 0 (0) |
| Sex (n (%)) | ||
| Girls | 12 (50) | 5 (31.3) |
| Boys | 12 (50) | 11 (68.7) |
| Duration of symptoms, months (mean ± SD) | 3.0 ± 2.7 | 3.7 ± 4.3 |
| Serum LDH concentration (mean ± SD) | 713.7 ± 710.6 | 383.1 ± 317.7 |
| Primary tumour site (n (%)) | ||
| Pelvis | 0 (0) | 1 (6.3) |
| Axial skeleton | 7 (29.2) | 4 (25) |
| Extremities | 15 (62.5) | 9 (56.2) |
| Internal organs and soft tissues | 2 (8.3) | 2 (12.5) |
| Cytogenetics (n (%)) | ||
| EWSR1/FLI1 | n.a. | 9 (56.3) |
| Dissemination at the time of diagnosis (n (%)) | ||
| Metastatic disease | 8 (33.3) | 4 (25) |
| Local disease | 16 (66.7) | 12 (75) |
| Treatment protocol (n (%)) | ||
| EuroEwing99 | 18 (75) | 16 (100) |
| VAC | 1 (4) | 0 |
| ET-2 | 1 (4) | 0 |
| IESS I | 1 (4) | 0 |
| IESS II | 1 (4) | 0 |
| NB90 | 1 (4) | 0 |
| Refused treatment | 1 (4) | 0 |
| HSCT (n (%)) | ||
| Performed | 14 (58.3) | 9 (56.3) |
| Not performed | 10 (41.7) | 7 (43.7) |
| Continuous complete remission (n (%)) | ||
| Alive in remission | 14 (58.3) | 12 (75) |
| Dead | 10 (41.7) | 4 (25) |
| Follow-up (years from diagnosis) | ||
| Median [min-max] | 12.3 (8.1–15.6) | 3.9 (1.1–8.0) |
n.a. – not assessed